Value Sense
POAI
Predictive Oncology Inc. (POAI)
Last Price$1.3(9.4%)
Market Cap$8,155.2K
LTM Net Change in Cash
($8,836.1K)
YoY Growth
-34.4%
3Y CAGR
N/A
5Y CAGR
+139.9%
Stock quality & Intrinsic value
4/10
297.3% undervalued
POAI
is 297.3% undervalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

Predictive Oncology Inc. Net Change in Cash

Annual
Quarterly
LTM
Crunching data... Almost there!
Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Net Change in Cash
$459.7K
($447.2K)
($7,249.0)
$113.6K
($109.8K)
$88.8K
($85.6K)
$4,839.8K
($3,092.1K)
($997.9K)
($604.0K)
($11.3K)
$527.5K
$27.5M
($6,131.1K)
($13.3M)
POAI
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for POAI and see if it's the right time to invest.
Dive in

Predictive Oncology Inc. (POAI) Net Change in Cash comparison analysis

General

LTM Net Change in Cash

Growth

Company name

YoY growth

3Y CAGR

5Y CAGR

Predictive Oncology Inc. logo
Predictive Oncology Inc.POAI
($8,836.1K)
(34.4%)
N/A
139.9%
Median Peer Set
($81.6M)
0.0%
0.0%
0.0%
ResMed Inc. logo
ResMed Inc.RMD
$311.7M
N/A
N/A
41.7%
Alcon Inc. logo
Alcon Inc.ALC
$278.0M
145.7%
149.0%
(14.1%)
Masimo Corporation logo
Masimo CorporationMASI
$16.6M
N/A
(45.6%)
1.5%
AptarGroup, Inc. logo
AptarGroup, Inc.ATR
$201.0K
(99.8%)
N/A
N/A
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
($13.2M)
(25.4%)
(13.2%)
N/A
Hologic, Inc. logo
Hologic, Inc.HOLX
($150.0M)
(70.5%)
N/A
N/A
West Pharmaceutical Services, Inc. logo
West Pharmaceutical Services, Inc.WST
($369.3M)
(47.9%)
N/A
N/A
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
($421.0M)
N/A
(33.0%)
(0.6%)
Intuitive Surgical, Inc. logo
Intuitive Surgical, Inc.ISRG
($687.7M)
N/A
27.4%
N/A
Baxter International Inc. logo
Baxter International Inc.BAX
($788.0M)
N/A
0.3%
N/A

POAI key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Dec'08Dec'09Dec'10Dec'11Dec'12Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Revenue
% growth
0.0
0.0%
0.0
0.0%
0.0
(98.2%)
0.1
33,454.5%
0.2
95.3%
0.5
148.0%
1.0
103.3%
0.7
(31.2%)
0.5
(30.2%)
0.7
43.4%
1.4
115.6%
1.4
(0.0%)
1.3
(11.3%)
1.4
13.4%
1.5
6.0%
1.8
18.2%
Cost of Goods Sold (COGS)0.00.00.00.10.10.20.40.30.20.10.40.50.40.50.50.6
Gross Profit
% margin
0.0
0.0%
0.0
55.5%
0.0
51.4%
0.0
42.0%
0.1
31.9%
0.3
59.5%
0.6
59.5%
0.4
53.5%
0.3
60.2%
0.5
77.4%
1.0
70.5%
0.9
62.3%
0.8
64.3%
0.9
65.7%
1.0
66.4%
1.1
64.3%
Operating Expenses1.72.51.24.17.29.27.04.86.88.38.914.713.314.416.315.1
Research & Development Expenses (R&D)0.00.00.00.00.00.20.40.30.40.31.93.02.40.30.30.2
Selling, General & Administrative Expenses (SG&A)1.42.02.14.17.29.27.04.85.68.37.011.710.911.712.510.9
Operating Income
% margin
(1.7)
0.0%
(2.4)
(15,528.1%)
(1.2)
(418,616.7%)
(4.1)
(4,248.3%)
(7.2)
(3,792.8%)
(8.9)
(1,907.1%)
(6.5)
(679.7%)
(4.4)
(672.4%)
(6.5)
(1,429.6%)
(7.7)
(1,183.0%)
(7.9)
(556.9%)
(13.8)
(975.8%)
(0.7)
(53.2%)
(13.5)
(948.2%)
(15.3)
(1,014.2%)
(13.9)
(782.1%)
Interest Income0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Interest Expense0.10.10.10.20.30.60.40.40.00.00.00.00.00.010.70.0
Pre-tax Income0.0(1.8)(1.4)(4.5)(7.4)(9.4)(6.8)(4.8)(6.5)(7.7)(10.1)(19.4)(25.9)(20.3)(25.7)(14.0)
Income Tax
% effective tax rate
0.1
0.0%
0.4
(25.4%)
0.0
0.0%
0.2
(5.1%)
0.3
(3.5%)
0.6
(6.8%)
0.4
(5.5%)
0.0
0.0%
0.0
0.0%
0.1
(0.7%)
(2.2)
22.1%
8.2
(42.1%)
11.8
(45.7%)
(0.7)
3.3%
10.5
(40.7%)
0.0
0.0%
Net Income
% margin
(1.8)
0.0%
(2.9)
(18,378.5%)
(1.4)
(469,690.6%)
(4.5)
(4,643.0%)
(7.4)
(3,931.8%)
(9.4)
(2,009.4%)
(6.8)
(718.1%)
(4.8)
(732.1%)
(6.5)
(1,429.6%)
(7.7)
(1,183.0%)
(10.1)
(714.5%)
(27.6)
(1,952.2%)
(37.7)
(3,010.7%)
(19.7)
(1,383.6%)
(36.2)
(2,405.1%)
(14.0)
(785.6%)
EPS(65,282.52)(96,407.67)(36,559.70)(52,786.81)(26,794.78)(16,051.71)(11,057.55)(4,601.85)(462.31)(243.50)(157.40)(192.02)(63.10)(7.16)(9.92)(3.48)
Diluted EPS(65,282.52)(96,407.67)(36,559.70)(52,786.81)(26,794.78)(16,051.71)(11,057.55)(4,601.85)(462.31)(243.50)(157.40)(192.02)(63.10)(7.16)(9.92)(3.48)
EBITDA
% margin
(1.7)
0.0%
(2.8)
(17,857.6%)
(1.2)
(417,773.3%)
(4.3)
(4,401.3%)
(7.2)
(3,793.9%)
(8.8)
(1,871.6%)
(6.4)
(671.8%)
(4.3)
(660.4%)
(6.4)
(1,411.5%)
(6.0)
(913.5%)
(7.7)
(546.4%)
(12.4)
(879.4%)
(11.5)
(915.0%)
(12.1)
(853.9%)
(14.0)
(926.9%)
(13.2)
(740.5%)

Discover more Stock Ideas

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks

Undervalued growth stocks

Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
More ideas -->

FAQ

1) What is Predictive Oncology Inc.'s Net Change in Cash?

As of today, Predictive Oncology Inc.'s last 12-month Net Change in Cash is ($8,836.1K), based on the financial report for Sep 30, 2024 (Q3’2024).

2) What is Predictive Oncology Inc.'s Net Change in Cash growth rate?

Over the last year, Predictive Oncology Inc.'s Net Change in Cash growth was (34.4%). The average annual Net Change in Cash growth rates for Predictive Oncology Inc. have been N/A over the past three years, 139.9% over the past five years.

3) Is Predictive Oncology Inc.'s Net Change in Cash growth rate Good?

Over the last year, Predictive Oncology Inc.'s Net Change in Cash growth was (34.4%), which is lower than industry growth of 2.3%. It indicates that Predictive Oncology Inc.'s Net Change in Cash growth is Bad.